1. EP-1366: Different toxicity rating patients and physicians in randomized phase III PCI vs obs stage III NSCLC. (April 2018) Authors: De Ruysscher, D.; Dingemans, A.; Praag, J.; Belderbos, J.; Tissing-Tan, C.; Herder, G.; Haitjema, T.; Ubbels, F.; Lagerwaard, F.; Stigt, J.; Smit, E.; Van Tinteren, H.; Van der Noort, V.; Groen, H. Journal: Radiotherapy and oncology Issue: Volume 127(2018)Supplement 1 Page Start: S745 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. High Protein Oral Nutritional Supplements Enable The Majority Of Cancer Patients To Meet ESPEN Protein Recommendations During Systemic Treatment. (April 2023) Authors: Dingemans, A.; van Walree, N.; Schramel, F.; Youssef-E Soud, M.; Baltruškevičienė, E.; Lybaert, W.; Veldhorst, M.; Van den Berg, C.; Kaasa, S. Journal: Clinical nutrition ESPEN Issue: Volume 54(2023) Page Start: 493 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OC-0176 Risk factors for cognitive impairment in NSCLC: Secondary findings of the NVALT-11 study. (August 2021) Authors: Zeng, H.; Hendriks, L.; Witlox, W.; Groen, H.; Dingemans, A.; Praag, J.; Belderbos, J.; Houben, R.; van der Noort, V.; De Ruysscher, D. Journal: Radiotherapy and oncology Issue: Volume 161(2021)supplement Page Start: S107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PD-0426: A clinical model predicting severe esophagitis in individual SCLC patients treated with chemo-radiotherapy. (April 2015) Authors: Reymen, B.; Oberije, C.; Van Loon, J.; Van Baardwijk, A.; Wanders, S.; Troost, E.; Hoebers, F.; Zindler, J.; Dingemans, A.; Bootsma, G.; Lunde, R.; Geraedts, W.; De Ruysscher, D.; Lambin, P. Journal: Radiotherapy and oncology Issue: Volume 115(2015)Supplement 1 Page Start: S207 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗